TABLE 1.
Selected populations and samples tested by TaqMan HIV-1 RNA real-time RT-PCR assaya
| ANRS Program | Tested subjects (n) | Tested samples
|
Test(s) for comparison | |
|---|---|---|---|---|
| n | Timing | |||
| ANRS 1201/1202 Ditrame Plus Program | ||||
| HIV-1-positive mothers | 177 | 177 | Pre-inclusion | Versant v3.0 |
| HIV-1-infected neonates | 28 | 57b | D2, W4, W6, M3, M6 | Versant v3.0 |
| Uninfected neonates | 230 | 230c | W4 | Versant v3.0 |
| ANRS 1220 Primo-ci Cohort, HIV-1 seroconverters | 101 | 101 | D0 | Monitor v1.5 and Versant v3.0 |
| ANRS 1244/1278 Children Program, HIV-1-infected children with HAART | 36 | 149d | D0, M6, M12, M18, M24 | Versant v3.0 |
| ANRS 1269 Trivacan Trial, HIV-1-infected adults with HAART | 46 | 92 | D0, M3 | Versant v3.0 |
| Total | 618 | 806 | ||
a
Samples were collected from 2001 to 2003 in Abidjan, Côte d'Ivoire (West Africa). D, day; W, week; M, month; v, version.
b
Specimens positive with the Versant assay v3.0, and drawn at day 2 (n = 9), weeks 4 to 6 (n = 39) and months 3 to 6 (n = 9) of life in 28 HIV-1-infected children (see Materials and Methods).
c
Including 210 samples negative and 20 specimens with false-positive results by using the Versant assay v3.0 and taken at week 4 of life in 230 HIV-1-uninfected children (see Materials and Methods).
d
31 samples missing due to insufficient volume (n = 11), deaths (n = 3), or loss or incomplete follow-up (n = 17).